Musculoskeletal tumors: How to use anatomic, functional, and metabolic MR techniques

Radiology

Volumn 265, Issue 2, 2012, Pages 340-356

  Fayad, Laura M ^a   Jacobs, Michael A ^a   Wang, Xin ^a   Carrino, John A ^a   Bluemke, David A ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANATOMY; CHEMICAL SHIFT IMAGING; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; METABOLISM; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PROCEDURES; REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE;

ADOLESCENT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; PROTONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867912528     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111740     Document Type: Review

References (119)

1. Miller SL, Hoffer FA. Malignant and benign bone tumors. Radiol Clin North Am 2001;39(4):673-699. (Pubitemid 32821153)
2. Kransdorf MJ, Jelinek JS, Moser RP Jr, et al. Soft-tissue masses: diagnosis using MR imaging. AJR Am J Roentgenol 1989;153(3):541-547. (Pubitemid 19210756)
3. Gielen JL, De Schepper AM, Vanhoenacker F, et al. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol 2004;14(12):2320-2330. (Pubitemid 40057945)
4. Zajick DC Jr, Morrison WB, Schweitzer ME, Parellada JA, Carrino JA. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology 2005;237(2):590-596. (Pubitemid 41507899)
5. Griffiths HJ, Thompson RC, Nitke SJ, Olson PN, Thielen KR, Amundson P. Use of MRI in evaluating postoperative changes in patients with bone and soft tissue tumors. Orthopedics 1997;20(3):215-220. (Pubitemid 27133563)
6. Lang P, Grampp S, Vahlensieck M, et al. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol 1995;165(1):135-142.
7. Pettersson H, Gillespy T 3rd, Hamlin DJ, et al. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities. Radiology 1987;164(1):237-241. (Pubitemid 17089911)
8. Belfi CA, Medendorp SV, Ngo FQ. The response of the KHT sarcoma to radiotherapy as measured by water proton NMR relaxation times: relationships with tumor volume and water content. Int J Radiat Oncol Biol Phys 1991;20(3):497-507.
9. Richardson ML, Amparo EG, Gillespy T 3rd, Helms CA, Demas BE, Genant HK. Theoretical considerations for optimizing intensity differences between primary musculoskeletal tumors and normal tissue with spin-echo magnetic resonance imaging. Invest Radiol 1985;20(5):492-497. (Pubitemid 15018712)
10. Jones KM, Schwartz RB, Mantello MT, et al. Fast spin-echo MR in the detection of vertebral metastases: comparison of three sequences. AJNR Am J Neuroradiol 1994;15(3):401-407. (Pubitemid 24089526)
11. Pozzi Mucelli R, Cova M, Shariat-Razavi I, Zucconi F, Ukmar M, Longo R. Comparison of magnetic resonance Spin-echo sequences and fat-suppressed sequences in bone diseases [in Italian]. Radiol Med (Torino) 1997;93(5):504-509. (Pubitemid 127513044)
12. Terk MR, Gober JR, de Verdier H, Simon HE, Colletti PM. Evaluation of suspected musculoskeletal neoplasms using 3D T2-weighted spectral presaturation with inversion recovery. Magn Reson Imaging 1993;11(7):931-939.
13. Disler DG, McCauley TR, Ratner LM, Kesack CD, Cooper JA. In-phase and out-of-phase MR imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. AJR Am J Roentgenol 1997;169(5):1439- 1447. (Pubitemid 27452518)
14. Eito K, Waka S, Naoko N, Makoto A, Atsuko H. Vertebral neoplastic compression fractures: assessment by dual-phase chemical shift imaging. J Magn Reson Imaging 2004;20(6):1020-1024. (Pubitemid 39577904)
15. Ragab Y, Emad Y, Gheita T, et al. Differentiation of osteoporotic and neoplastic vertebral fractures by chemical shift in-phase and out-of phase MR imaging. Eur J Radiol 2009;72(1):125-133.
16. Zampa V, Cosottini M, Michelassi C, Ortori S, Bruschini L, Bartolozzi C. Value of opposed-phase gradient-echo technique in distinguishing between benign and malignant vertebral lesions. Eur Radiol 2002;12(7):1811-1818. (Pubitemid 36940266)
17. Buxton RB, Wismer GL, Brady TJ, Rosen BR. Quantitative proton chemical-shift imaging. Magn Reson Med 1986;3(6):881-900.
18. Einarsdóttir H, Karlsson M, Wejde J, Bauer HC. Diffusion-weighted MRI of soft tissue tumours. Eur Radiol 2004;14(6):959-963. (Pubitemid 38787237)
19. Chenevert TL, Meyer CR, Moffat BA, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1(4):336-343.
20. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med 1995;33(5):697-712.
21. Le Bihan D. Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology 2008;249(3):748-752.
22. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109-1113. (Pubitemid 351614624)
23. Baur A, Huber A, Arbogast S, et al. Diffusion-weighted imaging of tumor recurrencies and posttherapeutical soft-tissue changes in humans. Eur Radiol 2001;11(5):828-833. (Pubitemid 32755532)
24. Baur A, Stäbler A, Brüning R, et al. Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures. Radiology 1998;207(2):349-356. (Pubitemid 28259047)
25. Herneth AM, Naude J, Philipp M, Beichel R, Trattnig S, Imhof H. The value of diffusion-weighted MRT in assessing the bone marrow changes in vertebral metastases [in German]. Radiologe 2000;40(8):731-736.
26. Herneth AM, Philipp MO, Naude J, et al. Vertebral metastases: assessment with apparent diffusion coefficient. Radiology 2002;225(3):889-894. (Pubitemid 35390381)
27. Hayashida Y, Hirai T, Yakushiji T, et al. Evaluation of diffusion-weighted imaging for the differential diagnosis of poorly contrast-enhanced and T2-prolonged bone masses: Initial experience. J Magn Reson Imaging 2006;23(3):377-382. (Pubitemid 43364065)
28. Nagata S, Nishimura H, Uchida M, et al. Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis. Radiat Med 2008;26(5):287-295.
29. Namimoto T, Yamashita Y, Awai K, et al. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2009;19(11):2756-2764.
30. Oka K, Yakushiji T, Sato H, et al. Ability of diffusion-weighted imaging for the differential diagnosis between chronic expanding hematomas and malignant soft tissue tumors. J Magn Reson Imaging 2008;28(5):1195-1200.
31. van Rijswijk CS, Kunz P, Hogendoorn PC, Taminiau AH, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging 2002;15(3):302-307. (Pubitemid 34195126)
32. Yakushiji T, Oka K, Sato H, et al. Characterization of chondroblastic osteosarcoma: gadolinium-enhanced versus diffusion-weighted MR imaging. J Magn Reson Imaging 2009;29(4):895-900.
33. Zhao M, Pipe JG, Bonnett J, Evelhoch JL. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996;73(1):61-64.
34. Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 2004;34(8):595-605. (Pubitemid 39162242)
35. De Keyzer F, Vandecaveye V, Thoeny H, et al. Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in single-dose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model. Eur Radiol 2009;19(11):2663-2671.
36. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 2006;16(12):2637-2643. (Pubitemid 44823917)
37. Kharuzhyk SA, Petrovskaya NA, Vosmitel MA. Diffusion-weighted magnetic resonance imaging in non-invasive monitoring of antiangiogenic therapy in experimental tumor model. Exp Oncol 2010;32(2):104-106.
38. Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 1998;206(1):227-235.
39. Oka K, Yakushiji T, Sato H, Hirai T, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol 2010;39(2):141-146.
40. Reichardt W, Juettner E, Uhl M, Elverfeldt DV, Kontny U. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest Radiol 2009;44(5):298-303.
41. Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2(6):581-587.
42. Schnapauff D, Zeile M, Niederhagen MB, et al. Diffusion-weighted echo-planar magnetic resonance imaging for the assessment of tumor cellularity in patients with soft-tissue sarcomas. J Magn Reson Imaging 2009;29(6):1355- 1359.
43. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234(3):756-764. (Pubitemid 40250819)
44. Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 2006;36(12):1306-1311. (Pubitemid 44920869)
45. Vossen JA, Kamel IR, Buijs M, et al. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr 2008;32(3):347-352.
46. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992;159(3):591-599.
47. Genovese E, Canì A, Rizzo S, Angeretti MG, Leonardi A, Fugazzola C. Comparison between MRI with spin-echo echo-planar diffusion-weighted sequence (DWI) and histology in the diagnosis of soft-tissue tumours. Radiol Med (Torino) 2011;116(4):644-656.
48. Mintorovitch J, Moseley ME, Chileuitt L, Shimizu H, Cohen Y, Weinstein PR. Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med 1991;18(1):39-50.
49. Fadul D, Fayad LM. Advanced modalities for the imaging of sarcoma. Surg Clin North Am 2008;88(3):521-537, vi. (Pubitemid 351736008)
50. Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol 2007;11(3):240-245. (Pubitemid 351272526)
51. Fayad LM, Barker PB, Jacobs MA, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol 2007;188(6):1513-1520. (Pubitemid 46866852)
52. Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging 2006;23(1):23-28. (Pubitemid 43100714)
53. Fayad LM, Salibi N, Wang X, et al. Quantification of muscle choline concentrations by proton MR spectroscopy at 3 T: technical feasibility. AJR Am J Roentgenol 2010;194(1):W73-W79.
54. Fayad LM, Wang X, Salibi N, et al. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. AJR Am J Roentgenol 2010;195(1):W69-W75.
55. Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. J Comput Assist Tomogr 2008;32(6):987-994.
56. Lee CW, Lee JH, Kim DH, et al. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification. Clin Imaging 2010;34(1):47-52.
57. Qi ZH, Li CF, Li ZF, Zhang K, Wang Q, Yu DX. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors. Chin Med J (Engl) 2009;122(1):39-43.
58. Sah PL, Sharma R, Kandpal H, et al. In vivo proton spectroscopy of giant cell tumor of the bone. AJR Am J Roentgenol 2008;190(2):W133-W139.
59. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology 2004;232(2):599-605.
60. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009;19(4):527-557.
61. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228(2):523-532. (Pubitemid 36910097)
62. Bajpai J, Gamanagatti S, Sharma MC, et al. Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer 2010;54(4):526-531.
63. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003;228(1):271-278. (Pubitemid 36736103)
64. Egmont-Petersen M, Hogendoorn PC, van der Geest RJ, et al. Detection of areas with viable remnant tumor in postchemotherapy patients with Ewing's sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling. Magn Reson Imaging 2000;18(5):525-535. (Pubitemid 30456376)
65. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 1990;175(3):791-796. (Pubitemid 20191948)
66. Guo JY, Reddick WE. DCE-MRI pixel-by-pixel quantitative curve pattern analysis and its application to osteosarcoma. J Magn Reson Imaging 2009;30(1):177-184.
67. Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 2004;426(426):32-38. (Pubitemid 39167104)
68. Lavini C, Pikaart BP, de Jonge MC, Schaap GR, Maas M. Region of interest and pixel-by-pixel analysis of dynamic contrast enhanced magnetic resonance imaging parameters and time-intensity curve shapes: a comparison in chondroid tumors. Magn Reson Imaging 2009;27(1):62-68.
69. Preda A, Wielopolski PA, Ten Hagen TL, et al. Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas. MAGMA 2004;17(3-6):296-302. (Pubitemid 40362313)
70. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 2001;91(12):2230-2237. (Pubitemid 32552807)
71. Schramm N, Schlemmer M, Rist C, Issels R, Reiser MF, Berger F. Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring [in German]. Radiologe 2010;50(4):339-348.
72. Shapeero LG, Vanel D. Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. Semin Musculoskelet Radiol 2000;4(1):137-146. (Pubitemid 30313151)
73. Toms AP, White LM, Kandel R, et al. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. Acta Radiol 2009;50(5):512-520.
74. Torricelli P, Montanari N, Spina V, et al. Dynamic contrast enhanced magnetic resonance imaging subtraction in evaluating osteosarcoma response to chemotherapy. Radiol Med (Torino) 2001;101(3):145-151. (Pubitemid 32471852)
75. Tuncbilek N, Karakas HM, Okten OO. Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol 2005;53(3):500-505. (Pubitemid 40312142)
76. van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol 2003;13(8):1849-1858. (Pubitemid 36949711)
77. .van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology 2004;233(2):493-502. (Pubitemid 39423810)
78. van Rijswijk CS, Hogendoorn PC, Taminiau AH, Bloem JL. Synovial sarcoma: dynamic contrast-enhanced MR imaging features. Skeletal Radiol 2001;30(1):25-30. (Pubitemid 32170945)
79. Viglianti BL, Lora-Michiels M, Poulson JM, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 2009;15(15):4993-5001.
80. Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 2006;41(8):618-623. (Pubitemid 44284169)
81. Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA - enhanced MR imaging. Radiology 1989;171(3):767-773. (Pubitemid 19134937)
82. Korosec FR, Frayne R, Grist TM, Mistretta CA. Time-resolved contrast-enhanced 3D MR angiography. Magn Reson Med 1996;36(3):345-351. (Pubitemid 26299259)
83. Song T, Laine AF, Chen Q, et al. Optimal k-space sampling for dynamic contrast-enhanced MRI with an application to MR renography. Magn Reson Med 2009;61(5):1242-1248.
84. Hawighorst H, Libicher M, Knopp MV, Moehler T, Kauffmann GW, Kaick G. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 1999;10(3):286-294. (Pubitemid 29463111)
85. van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 1998;208(3):821-828. (Pubitemid 28405123)
86. Alic L, van Vliet M, van Dijke CF, Eggermont AM, Veenland JF, Niessen WJ. Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? Phys Med Biol 2011;56(6):1601-1616.
87. Huang W, Wang Y, Panicek DM, Schwartz LH, Koutcher JA. Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging 2009;27(6):852-858.
88. Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999;10(6):903-907.
89. Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J 2011;13(1):111-120.
90. van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol 1995;165(3):593-598.
91. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30(2):298-308.
92. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010;39(4):333-343.
93. Hayes CW, Conway WF, Sundaram M. Misleading aggressive MR imaging appearance of some benign musculoskeletal lesions. RadioGraphics 1992;12(6):1119-1134; discussion 1135-1136.
94. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology 1992;185(2):581-586.
95. Moulton JS, Blebea JS, Dunco DM, Braley SE, Bisset GS 3rd, Emery KH. MR imaging of soft-tissue masses: diagnostic efficacy and value of distinguishing between benign and malignant lesions. AJR Am J Roentgenol 1995;164(5):1191-1199.
96. Ma LD, Frassica FJ, McCarthy EF, Bluemke DA, Zerhouni EA. Benign and malignant musculoskeletal masses: MR imaging differentiation with rim-to-center differential enhancement ratios. Radiology 1997;202(3):739-744. (Pubitemid 27093449)
97. Bodner G, Schocke MF, Rachbauer F, et al. Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. Radiology 2002;223(2):410-416. (Pubitemid 34454319)
98. Rydholm A. Improving the management of soft tissue sarcoma. Diagnosis and treatment should be given in specialist centres. BMJ 1998;317(7151):93-94.
99. Yang J, Frassica FJ, Fayad L, Clark DP, Weber KL. Analysis of nondiagnostic results after image-guided needle biopsies of musculoskeletal lesions. Clin Orthop Relat Res 2010;468(11):3103-3111.
100. Hermann G, Abdelwahab IF, Miller TT, Klein MJ, Lewis MM. Tumour and tumour-like conditions of the soft tissue: magnetic resonance imaging features differentiating benign from malignant masses. Br J Radiol 1992;65(769):14-20.
101. Ma LD, McCarthy EF, Bluemke DA, Frassica FJ. Differentiation of benign from malignant musculoskeletal lesions using MR imaging: pitfalls in MR evaluation of lesions with a cystic appearance. AJR Am J Roentgenol 1998;170(5):1251-1258. (Pubitemid 28210939)
102. Verstraete KL, Vanzieleghem B, De Deene Y, et al. Static, dynamic and first-pass MR imaging of musculoskeletal lesions using gadodiamide injection. Acta Radiol 1995;36(1):27-36.
103. Fayad LM, Kamel IR, Kawamoto S, Bluemke DA, Frassica FJ, Fishman EK. Distinguishing stress fractures from pathologic fractures: a multimodality approach. Skeletal Radiol 2005;34(5):245-259. (Pubitemid 41166698)
104. Tamai K, Koyama T, Saga T, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008;18(4):723-730. (Pubitemid 351447778)
105. Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988;168(3):679-693.
106. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011;47(6):895-902.
107. Hegyi M, Semsei AF, Jakab Z, et al. Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer 2011;57(3):415-422. [Published correction appears in Pediatr Blood Cancer 2012;58(4):654.]
108. Donahue TR, Kattan MW, Nelson SD, Tap WD, Eilber FR, Eilber FC. Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer 2010;116(16):3883-3891.
109. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19(13):3203-3209. (Pubitemid 32591437)
110. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-150S.
111. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251(2):447-456.
112. Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol 2010;97(3):404-407.
113. Lang P, Johnston JO, Arenal-Romero F, Gooding CA. Advances in MR imaging of pediatric musculoskeletal neoplasms. Magn Reson Imaging Clin N Am 1998;6(3):579-604. (Pubitemid 28354599)
114. Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2011;35(2):167-173.
115. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol 2011;38(1):26-41.
116. Jansen JF, Schöder H, Lee NY, et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 2012;82(1):299-307.
117. Vöglein J, Tüttenberg J, Weimer M, et al. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol 2011;46(6):390-400.
118. Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology 1987;164(1):243-245. (Pubitemid 17089912)
119. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology 1994;190(1):263-268.